Skip to content

Researchers successfully develop placenta-on-a-chip which mirrors what occurs in the human body.

National Institutes of Health (NIH) researchers and their colleagues have developed a ‘placenta-on-a-chip’ to study the inner workings of the human placenta and its role in pregnancy. The device was designed to imitate the structure and function of the placenta and model the transfer of nutrients from mother to fetus. This prototype is one of the latest in a series of organ-on-a-chip technologies developed to accelerate biomedical advances.  The opensource study is published in the Journal of Maternal-Fetal & Neonatal Medicine.

The team state that this technology may be used to address questions that are difficult to answer with current placenta model systems and help enable research on pregnancy and its complications.

Previous studies show that the placenta is a temporary organ that develops in pregnancy and is the major interface between mother and fetus. Among its many functions is to serve as a ‘crossing guard’ for substances traveling between mother and fetus. The placenta helps nutrients and oxygen move to the fetus and helps waste products move away. At the same time, the placenta tries to stop harmful environmental exposures, like bacteria, viruses and certain medications, from reaching the fetus. When the placenta doesn’t function correctly, the health of both mom and baby suffers.

The team explain that researchers are currently trying to learn how the placenta manages all this traffic, transporting some substances and blocking others. This knowledge may one day help clinicians better assess placental health and ultimately improve pregnancy outcomes.  However, studying the placenta in humans is challenging, state the team, it is time-consuming, subject to a great deal of variability and potentially risky for the fetus. For those reasons, previous studies on placental transport have relied largely on animal models and on laboratory-grown human cells. These methods have yielded helpful information, but are limited as to how well they can mimic physiological processes in humans.

In the current study a placenta-on-a-chip technology was developed to address these challenges, using human cells in a structure that more closely resembles the placenta’s maternal-fetal barrier. The device consists of a semi-permeable membrane between two tiny chambers, one filled with maternal cells derived from a delivered placenta and the other filled with fetal cells derived from an umbilical cord.

After designing the structure of the model, the researchers tested its function by evaluating the transfer of glucose (a substance made by the body when converting carbohydrates to energy) from the maternal compartment to the fetal compartment. The successful transfer of glucose in the device mirrored what occurs in the body.

The team surmise that the chip may allow the medical community to do experiments more efficiently and at a lower cost than animal studies.  With further improvements the researchers hope that this technology may lead to better understanding of normal placental processes and placental disorders.

Source:  National Institutes of Health (NIH)

 

 A placenta-on-a-chip microdevice: (A) The microengineered device is composed of the upper (blue) and lower (red) PDMS chambers separated by a vitrified collagen membrane. (B) Endothelial cells and trophoblasts are co-cultured in close apposition on the opposite sides of the intervening membrane to form a microengineered placental barrier in the placenta-on-a-chip device.  Placenta-on-a-chip: a novel platform to study the biology of the human placenta.  Huh et al 2015.
A placenta-on-a-chip microdevice: (A) The microengineered device is composed of the upper (blue) and lower (red) PDMS chambers separated by a vitrified collagen membrane. (B) Endothelial cells and trophoblasts are co-cultured in close apposition on the opposite sides of the intervening membrane to form a microengineered placental barrier in the placenta-on-a-chip device. Placenta-on-a-chip: a novel platform to study the biology of the human placenta. Huh et al 2015.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

Leave a Reply

Translate »